Communiqués Artelo Biosciences, Inc.

Actions

ARTL

US04301G8050

Recherche biotechnologique et médicale

Temps Différé Nasdaq 17:33:21 09/09/2026			Varia. 5j.	Varia. 1 janv.
6,070 ^USD	-1,94%		-6,90%	-81,57%

20/08	Artelo Biosciences obtient un avis d'acceptation au Japon pour les revendications de brevet de la formulation commerciale de l'ART27.13	CI
17/08	Artelo Biosciences reçoit un avis d'acceptation de brevet aux États-Unis pour la formulation commerciale de l'ART27.13	CI

Communiqués

08/09	Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
27/08	Artelo Biosciences Announces Reverse Stock Split	AQ
20/08	Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13	AQ
17/08	Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies	AQ
13/08	Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results	AQ
10/08	Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma	AQ
23/07	New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy, Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition	AQ
22/07	New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition	AQ
16/07	Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions	AQ
14/07	Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026	AQ
13/07	Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy	AQ
01/07	Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury	AQ
30/06	Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026	AQ
29/06	Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026	AQ
10/06	Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success	AQ
14/05	Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results	AQ
28/04	Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development	AQ
20/04	Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile	AQ
07/04	Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements	AQ
27/03	Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	AQ
25/03	Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments	AQ
25/03	Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength	AQ
18/03	Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study	AQ
18/03	Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients	AQ
06/03	Artelo Biosciences Announces Reverse Stock Split	AQ